{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:11:53Z","timestamp":1777479113693,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":645,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1038\/mtm.2015.6","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T14:15:46Z","timestamp":1426083346000},"page":"15006","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection"],"prefix":"10.1016","volume":"2","author":[{"given":"Aintzane","family":"Zabaleta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia","family":"D'Avola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Llopiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyre","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorea","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Ignacio","family":"Riezu-Boj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Larrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Pereboev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Lasarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iago","family":"Rodriguez-Lago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"I\u00f1arrairaegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Sangro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Sarobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mtm.2015.6_bib1","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0140-6736(95)91691-1","article-title":"Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection","volume":"346","author":"Diepolder","year":"1995","journal-title":"Lancet"},{"key":"10.1038\/mtm.2015.6_bib2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI118842","article-title":"Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response","volume":"98","author":"Missale","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1038\/mtm.2015.6_bib3","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.194.10.1395","article-title":"Determinants of viral clearance and persistence during acute hepatitis C virus infection","volume":"194","author":"Thimme","year":"2001","journal-title":"J Exp Med"},{"key":"10.1038\/mtm.2015.6_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1586\/erv.11.55","article-title":"Vaccination for hepatitis C virus: closing in on an evasive target","volume":"10","author":"Halliday","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1038\/mtm.2015.6_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jhep.2010.09.040","article-title":"Progress in the development of preventive and therapeutic vaccines for hepatitis C virus","volume":"54","author":"Torresi","year":"2011","journal-title":"J Hepatol"},{"key":"10.1038\/mtm.2015.6_bib6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1053\/j.gastro.2008.02.058","article-title":"Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41","volume":"134","author":"Klade","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1038\/mtm.2015.6_bib7","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1016\/j.vaccine.2009.06.027","article-title":"Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C","volume":"27","author":"Wedemeyer","year":"2009","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2015.6_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2010.05.007","article-title":"A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals","volume":"53","author":"Gowans","year":"2010","journal-title":"J Hepatol"},{"key":"10.1038\/mtm.2015.6_bib9","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/mt.2013.119","article-title":"Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C","volume":"21","author":"Weiland","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2015.6_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2014.03.007","article-title":"Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection","volume":"147","author":"Di Bisceglie","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1038\/mtm.2015.6_bib11","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/ni.2467","article-title":"Re(de)fining the dendritic cell lineage","volume":"13","author":"Satpathy","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1038\/mtm.2015.6_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","article-title":"Cancer immunotherapy via dendritic cells","volume":"12","author":"Palucka","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mtm.2015.6_bib13","doi-asserted-by":"crossref","first-page":"e25771","DOI":"10.4161\/onci.25771","article-title":"Trial watch: Dendritic cell-based interventions for cancer therapy","volume":"2","author":"Vacchelli","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1038\/mtm.2015.6_bib14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/sj.mt.6300333","article-title":"Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein","volume":"16","author":"Zabaleta","year":"2008","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2015.6_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.24325","article-title":"Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells","volume":"54","author":"Echeverria","year":"2011","journal-title":"Hepatology"},{"key":"10.1038\/mtm.2015.6_bib16","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1128\/JVI.02021-06","article-title":"Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression","volume":"81","author":"Radziewicz","year":"2007","journal-title":"J Virol"},{"key":"10.1038\/mtm.2015.6_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.21541","article-title":"Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection","volume":"45","author":"Penna","year":"2007","journal-title":"Hepatology"},{"key":"10.1038\/mtm.2015.6_bib18","doi-asserted-by":"crossref","first-page":"9249","DOI":"10.1128\/JVI.00409-07","article-title":"Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction","volume":"81","author":"Golden-Mason","year":"2007","journal-title":"J Virol"},{"key":"10.1038\/mtm.2015.6_bib19","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1128\/JVI.00639-09","article-title":"Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells","volume":"83","author":"Golden-Mason","year":"2009","journal-title":"J Virol"},{"key":"10.1038\/mtm.2015.6_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1600-0625.2009.00975.x","article-title":"CD40 signalling induces IL-10-producing, tolerogenic dendritic cells","volume":"19","author":"Tuettenberg","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1038\/mtm.2015.6_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hep.23980","article-title":"Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10","volume":"53","author":"D\u00edaz-Vald\u00e9s","year":"2011","journal-title":"Hepatology"},{"key":"10.1038\/mtm.2015.6_bib22","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gutjnl-2011-300620","article-title":"T cell responses in hepatitis C: the good, the bad and the unconventional","volume":"61","author":"Klenerman","year":"2012","journal-title":"Gut"},{"key":"10.1038\/mtm.2015.6_bib23","doi-asserted-by":"crossref","first-page":"e39368","DOI":"10.1371\/journal.pone.0039368","article-title":"Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals","volume":"7","author":"Li","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1038\/mtm.2015.6_bib24","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1016\/j.vaccine.2006.03.009","article-title":"Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects","volume":"24","author":"Firbas","year":"2006","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2015.6_bib25","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2015.6_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1086\/597072","article-title":"Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection","volume":"199","author":"Barnes","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1038\/mtm.2015.6_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3748\/wjg.v8.i3.562","article-title":"HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C","volume":"8","author":"Woitas","year":"2002","journal-title":"World J Gastroenterol"},{"key":"10.1038\/mtm.2015.6_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2893.2009.01094.x","article-title":"Low interleukin-10 production by monocytes of patients with a self-limiting hepatitis C virus infection","volume":"16","author":"Martin-Blondel","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1038\/mtm.2015.6_bib29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1189\/jlb.1210680","article-title":"Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections","volume":"89","author":"Liu","year":"2011","journal-title":"J Leukoc Biol"},{"key":"10.1038\/mtm.2015.6_bib30","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.4049\/jimmunol.170.11.5615","article-title":"Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation","volume":"170","author":"Dolganiuc","year":"2003","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2015.6_bib31","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1002\/eji.200324251","article-title":"Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes","volume":"33","author":"Brady","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1038\/mtm.2015.6_bib32","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1128\/JVI.02547-07","article-title":"Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production","volume":"82","author":"Saito","year":"2008","journal-title":"J Virol"},{"key":"10.1038\/mtm.2015.6_bib33","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.4049\/jimmunol.160.4.1666","article-title":"The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation","volume":"160","author":"de Saint-Vis","year":"1998","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2015.6_bib34","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.4049\/jimmunol.166.7.4312","article-title":"Regulatory activity of autocrine IL-10 on dendritic cell functions","volume":"166","author":"Corinti","year":"2001","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2015.6_bib35","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.4049\/jimmunol.179.7.4520","article-title":"Pathogen-specific CD8 T cell responses are directly inhibited by IL-10","volume":"179","author":"Biswas","year":"2007","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2015.6_bib36","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.4049\/jimmunol.180.8.5423","article-title":"Abrogation of anti-retinal autoimmunity in IL-10 transgenic mice due to reduced T cell priming and inhibition of disease effector mechanisms","volume":"180","author":"Agarwal","year":"2008","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2015.6_bib37","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.4049\/jimmunol.0803567","article-title":"Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity","volume":"183","author":"Schreiber","year":"2009","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2015.6_bib38","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1073\/pnas.0914500107","article-title":"IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection","volume":"107","author":"Brooks","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtm.2015.6_bib39","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.4049\/jimmunol.177.4.2565","article-title":"IL-10 is required for optimal CD8 T cell memory following Listeria monocytogenes infection","volume":"177","author":"Foulds","year":"2006","journal-title":"J Immunol"},{"key":"10.1038\/mtm.2015.6_bib40","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.immuni.2011.09.017","article-title":"An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells","volume":"35","author":"Cui","year":"2011","journal-title":"Immunity"},{"key":"10.1038\/mtm.2015.6_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116300183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050116300183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T17:56:46Z","timestamp":1691517406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050116300183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":41,"alternative-id":["S2329050116300183"],"URL":"https:\/\/doi.org\/10.1038\/mtm.2015.6","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]},"article-number":"15006"}}